CancerVax, YM Bio and CIMAB in cancer deal
Cancer therapeutics company CancerVax's Tarcanta and Tarcanta Ltd. subsidiaries have licensed from CIMAB SA (commercial branch of Cuba's Center of Molecular Immunology and YM BioSciences (cancer; has an existing relationship with YM) exclusive rights to complete clinical development on three oncology immunotherapeutics. CancerVax also gets rights to commercialize successful products from the deal in the US, Western Europe, Canada, Japan, Australia, New Zealand, and Mexico.
- Large Molecule
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com